Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting

Stock Information for Clean Energy Technologies Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Clean Energy Technologies Inc.

Bolt Biotherapeutics to Participate in Upcoming March Conferences
Bolt Biotherapeutics, Inc. Provides Update on Global Cancer Immunotherapy Co-Development with Toray Industries, Inc.
Bolt Biotherapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Bolt Biotherapeutics, Inc. May Have Violated Securities Laws And Shareholders Are Urged To Participate In A Case With The Schall Law Firm
The Schall Law Firm Invites Investors To Contribute To A Securities Fraud Lawsuit Against Bolt Biotherapeutics Inc
Bolt Biotherapeutics Announces Changes to its Board of Directors
Bolt Biotherapeutics Inc. May Have Violated Securities Regulations And Stakeholders Are Urged To Reach Out To The Schall Law Firm
BOLT DEADLINE TODAY: ROSEN, A LEADING LAW FIRM, Encourages Bolt Biotherapeutics, Inc. Investors to Secure Counsel Before Important September 3 Deadline in Securities Class Action - BOLT

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.